Literature DB >> 8884219

Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha.

C D McWhinney1, M W Dudley, T L Bowlin, N P Peet, L Schook, M Bradshaw, M De, D R Borcherding, C K Edwards.   

Abstract

Murine macrophage-derived tumor necrosis factor alpha (TNF-alpha) gene expression has been shown to be dramatically induced by bacterial lipopolysaccharide, and to be dependent upon nuclear factor-kappa B (NF-kappa B) binding sites in its promoter for the lipopolysaccharide induction. Murine J774.1 macrophage cells were found to predominantly express the adenosine A3 receptor RNA relative to adenosine A1 receptor or adenosine A2 receptor RNA. Adenosine receptor agonists, in a dose-dependent manner characteristic of the adenosine A3 receptor, blocked the endotoxin induction of the TNF-alpha gene and TNF-alpha protein expression in the J774.1 macrophage cell line. The adenosine A3 receptor antagonist BW-1433 dose-dependently reversed this adenosine inhibitory effect on TNF-alpha gene expression. Thus, the binding of adenosine receptor agonists to the adenosine A3 receptor interrupts the endotoxin CD14 receptor signal transduction pathway and blocks induction of cytokine TNF-alpha, revealing a novel cross-talk between the murine adenosine A3 receptor and the endotoxin CD14 receptor in J774.1 macrophages.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8884219     DOI: 10.1016/0014-2999(96)00272-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

Review 1.  IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors:  G Haskó; C Szabó
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

Review 2.  Possible targeting of G protein coupled receptors to manipulate inflammation in vivo using synthetic and natural ligands.

Authors:  J F Kinsel; M V Sitkovsky
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases.

Authors:  Bruce N Cronstein; Michail Sitkovsky
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

Review 4.  Shaping of monocyte and macrophage function by adenosine receptors.

Authors:  György Haskó; Pál Pacher; Edwin A Deitch; E Sylvester Vizi
Journal:  Pharmacol Ther       Date:  2006-09-14       Impact factor: 12.310

5.  Adenosine augments IL-10 production by macrophages through an A2B receptor-mediated posttranscriptional mechanism.

Authors:  Zoltán H Németh; Carol S Lutz; Balázs Csóka; Edwin A Deitch; S Joseph Leibovich; William C Gause; Masahide Tone; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

6.  Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB.

Authors:  B N Cronstein; M C Montesinos; G Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

Review 7.  Investigational A₃ adenosine receptor targeting agents.

Authors:  Balázs Koscsó; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Expert Opin Investig Drugs       Date:  2011-04-02       Impact factor: 6.206

8.  Adenosine reduces cell surface expression of toll-like receptor 4 and inflammation in response to lipopolysaccharide and matrix products.

Authors:  Benjamin Haas; Frederique Leonard; Isabelle Ernens; Sophie Rodius; Melanie Vausort; Magali Rolland-Turner; Yvan Devaux; Daniel R Wagner
Journal:  J Cardiovasc Transl Res       Date:  2011-05-03       Impact factor: 4.132

Review 9.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

10.  Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes.

Authors:  Jon G Mabley; Alex Rabinovitch; Wilma Suarez-Pinzon; György Haskó; Pál Pacher; Robert Power; Gary Southan; Andrew Salzman; Csaba Szabó
Journal:  Mol Med       Date:  2003 Mar-Apr       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.